Despite lung cancer being the leading cause of cancer mortality, its survival rate has continued to increase over the past 5 years. However, disparities in early diagnosis, treatment options and access, survival rate, and more remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for lung cancer, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters BriefCase, a faculty expert will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with lung cancer. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve lung cancer treatment.
At the end of this CME/CE activity, participants should be able to recognize the impact of health inequities on patients with lung cancer and develop individual treatment strategies for optimal clinical outcomes.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses/nurse navigators, dietitians, pharmacists, specializing in oncology, pathology, radiology, pulmonology, and primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mitchell reports the following financial relationships: Advisory Board: Corvus Pharmaceuticals, Inc. Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Velázquez Mañana reports the following financial relationships: Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc. Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 0.5 contact hours